COMMUNIQUÉS West-GlobeNewswire

-
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
29/04/2024 -
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
29/04/2024 -
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
29/04/2024 -
Cerevance to Participate at Upcoming Investor Conferences
29/04/2024 -
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
29/04/2024 -
Verspeeten Family Cancer Centre Unveiling Marks a Historic Milestone in Cancer Research and Treatment
29/04/2024 -
Smart For Life to Attend National Pet Food Forum on April 29 to May 2
29/04/2024 -
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
29/04/2024 -
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
29/04/2024 -
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29/04/2024 -
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
29/04/2024 -
Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidate
29/04/2024 -
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
29/04/2024 -
SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024
29/04/2024 -
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
29/04/2024 -
PetMed Express, Inc. Names Sandra Campos as new Chief Executive Officer and President
29/04/2024 -
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
29/04/2024 -
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
29/04/2024 -
Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers
29/04/2024
Pages